Bank of New York Mellon Corp Buys 871 Shares of Eiger BioPharmaceuticals, Inc. (EIGR)
Bank of New York Mellon Corp boosted its stake in Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) by 6.4% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 14,567 shares of the biotechnology company’s stock after acquiring an additional 871 shares during the period. Bank of New York Mellon Corp owned 0.17% of Eiger BioPharmaceuticals worth $115,000 as of its most recent SEC filing.
Separately, LMR Partners LLP acquired a new position in Eiger BioPharmaceuticals in the 2nd quarter valued at about $116,000. 61.04% of the stock is currently owned by hedge funds and other institutional investors.
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) opened at $10.60 on Wednesday. The company has a debt-to-equity ratio of 0.72, a current ratio of 7.01 and a quick ratio of 7.01. Eiger BioPharmaceuticals, Inc. has a 52-week low of $6.10 and a 52-week high of $13.95.
COPYRIGHT VIOLATION WARNING: This article was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://www.thecerbatgem.com/2017/11/08/bank-of-new-york-mellon-corp-buys-871-shares-of-eiger-biopharmaceuticals-inc-eigr.html.
In other news, Director Jeffrey S. Glenn purchased 15,000 shares of the firm’s stock in a transaction dated Friday, September 1st. The shares were acquired at an average price of $9.53 per share, with a total value of $142,950.00. Following the purchase, the director now directly owns 31,355 shares of the company’s stock, valued at $298,813.15. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 28.80% of the stock is owned by insiders.
Several equities analysts recently issued reports on the company. Oppenheimer Holdings, Inc. set a $34.00 price target on Eiger BioPharmaceuticals and gave the company a “buy” rating in a research report on Monday, October 23rd. Zacks Investment Research upgraded Eiger BioPharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a research report on Monday, October 16th. BTIG Research began coverage on Eiger BioPharmaceuticals in a research report on Friday, July 14th. They set a “buy” rating and a $32.00 target price on the stock. Roth Capital began coverage on Eiger BioPharmaceuticals in a research report on Thursday, October 19th. They set a “buy” rating and a $35.00 target price on the stock. Finally, ValuEngine upgraded Eiger BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $30.43.
Eiger BioPharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.
Want to see what other hedge funds are holding EIGR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR).
Receive News & Stock Ratings for Eiger BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals Inc. and related stocks with our FREE daily email newsletter.